Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 9043
Country/Region: Uganda
Year: 2017
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $9,490,422 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,514,522
Care: Orphans and Vulnerable Children (HKID) $1,156,803
Care: TB/HIV (HVTB) $754,488
Care: Pediatric Care and Support (PDCS) $81,063
Laboratory Infrastructure (HLAB) $225,450
Strategic Information (HVSI) $750,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $375,101
Sexual Prevention: Abstinence/Be Faithful (HVAB) $3,867
Prevention: HIV Testing and Counseling (HVCT) $615,353
Sexual Prevention: Other Sexual Prevention (HVOP) $977,817
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $348,893
Treatment: Adult Treatment (HTXS) $2,635,628
Treatment: Pediatric Treatment (PDTX) $51,437
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD 10-14, Female, Physical and/or Emotional Violence 2018 1
GEND_GBV_DSD 10-14, Female, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV_DSD 10-14, Male, Sexual Violence (Post-Rape Care) 2018 1
GEND_GBV_DSD 15-19, Female, Physical and/or Emotional Violence 2018 2
GEND_GBV_DSD 15-19, Female, Sexual Violence (Post-Rape Care) 2018 8
GEND_GBV_DSD 15-19, Male, Physical and/or Emotional Violence 2018 1
GEND_GBV_DSD 15-19, Male, Sexual Violence (Post-Rape Care) 2018 1
GEND_GBV_DSD 20-24, Female, Physical and/or Emotional Violence 2018 2
GEND_GBV_DSD 20-24, Female, Sexual Violence (Post-Rape Care) 2018 9
GEND_GBV_DSD 20-24, Male, Physical and/or Emotional Violence 2018 1
GEND_GBV_DSD 20-24, Male, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV_DSD 25-49, Female, Physical and/or Emotional Violence 2018 2
GEND_GBV_DSD 25-49, Female, Sexual Violence (Post-Rape Care) 2018 25
GEND_GBV_DSD 25-49, Male, Physical and/or Emotional Violence 2018 1
GEND_GBV_DSD 25-49, Male, Sexual Violence (Post-Rape Care) 2018 7
GEND_GBV_DSD 50+, Female, Physical and/or Emotional Violence 2018 2
GEND_GBV_DSD 50+, Female, Sexual Violence (Post-Rape Care) 2018 9
GEND_GBV_DSD 50+, Male, Physical and/or Emotional Violence 2018 1
GEND_GBV_DSD 50+, Male, Sexual Violence (Post-Rape Care) 2018 7
GEND_GBV_DSD <10, Female, Physical and/or Emotional Violence 2018 1
GEND_GBV_DSD <10, Female, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV_DSD <10, Male, Sexual Violence (Post-Rape Care) 2018 1
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2018 74
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 151
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2018 522
GEND_GBV_DSD Number of people receiving post-GBV care 2018 835
GEND_GBV_TA 15-19, Female, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV_TA 20-24, Female, Sexual Violence (Post-Rape Care) 2018 3
GEND_GBV_TA 20-24, Male, Sexual Violence (Post-Rape Care) 2018 1
GEND_GBV_TA 25-49, Female, Sexual Violence (Post-Rape Care) 2018 39
GEND_GBV_TA 25-49, Male, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV_TA 50+, Female, Sexual Violence (Post-Rape Care) 2018 3
GEND_GBV_TA 50+, Male, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV_TA By PEP service provision (related to sexual violence services provided) 2018 49
GEND_GBV_TA By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 93
GEND_GBV_TA By type of service: Sexual Violence (Post-Rape Care) 2018 338
GEND_GBV_TA Number of people receiving post-GBV care 2018 532
HTC_TST_DSD By Test Result: Positive 2018 17,039
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 207,468
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 1-9, Negative 2018 126
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 1-9, Positive 2018 2
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Female, Negative 2018 8
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Male, Negative 2018 8
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2018 33
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2018 14
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2018 5
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2018 132
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2018 68
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2018 37
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2018 18
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 25-49, Female, Negative 2018 1,021
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 25-49, Female, Positive 2018 586
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 25-49, Male, Negative 2018 1,448
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 25-49, Male, Positive 2018 817
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2018 94
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 50+, Female, Positive 2018 50
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2018 172
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2018 100
HTC_TST_DSD Service Delivery Point (Community) Index Mod: <1, Negative 2018 72
HTC_TST_DSD Service Delivery Point (Community) Index Mod: <1, Positive 2018 1
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2018 780
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2018 84
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2018 2,333
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2018 260
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2018 1,554
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2018 173
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2018 3,885
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2018 442
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative 2018 1,536
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive 2018 168
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative 2018 3,885
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive 2018 436
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2018 777
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive 2018 81
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2018 777
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2018 81
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Negative 2018 14,003
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Positive 2018 487
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Negative 2018 16,334
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Positive 2018 561
HTC_TST_DSD Service Delivery Point (Facility) ANC: 25-49, Negative 2018 14,003
HTC_TST_DSD Service Delivery Point (Facility) ANC: 25-49, Positive 2018 487
HTC_TST_DSD Service Delivery Point (Facility) ANC: 50+, Negative 2018 2,335
HTC_TST_DSD Service Delivery Point (Facility) ANC: 50+, Positive 2018 82
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Negative 2018 227
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Positive 2018 4
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 23
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 23
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 125
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 73
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 32
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 15
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 422
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 236
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 145
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 80
HTC_TST_DSD Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 3,219
HTC_TST_DSD Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 1,818
HTC_TST_DSD Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 4,724
HTC_TST_DSD Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 2,657
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 314
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Female, Positive 2018 175
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 582
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Positive 2018 323
HTC_TST_DSD Service Delivery Point (Facility) Index: <1, Negative 2018 153
HTC_TST_DSD Service Delivery Point (Facility) Index: <1, Positive 2018 2
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Negative 2018 380
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Positive 2018 4
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2018 39
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2018 86
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2018 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 800
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2018 38
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 172
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2018 7
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 2,594
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 123
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 721
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2018 37
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 15,373
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 858
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 18,303
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 1,121
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2018 1,507
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2018 84
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2018 2,258
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2018 138
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: <1, Negative 2018 332
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: <1, Positive 2018 6
HTC_TST_DSD Service Delivery Point (Facility) Malnutrition: Negative 2018 35
HTC_TST_DSD Service Delivery Point (Facility) Malnutrition: Positive 2018 1
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 378
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 6
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 40
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 72
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 817
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 53
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 141
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 9
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 2,755
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 188
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 660
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 52
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 17,967
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 1,302
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 21,252
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 1,747
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 1,766
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 126
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 2,589
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 213
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: <1, Positive 2018 4
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Negative 2018 397
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Positive 2018 5
HTC_TST_DSD Service Delivery Point (Facility) TB: 1-9, Negative 2018 33
HTC_TST_DSD Service Delivery Point (Facility) TB: 1-9, Positive 2018 1
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 3
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 18
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 3
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 2
HTC_TST_DSD Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 150
HTC_TST_DSD Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 69
HTC_TST_DSD Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 197
HTC_TST_DSD Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 82
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 10
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Female, Positive 2018 1
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 20
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Positive 2018 7
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 15-19, Negative 2018 6,877
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 15-19, Positive 2018 55
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 20-24, Negative 2018 8,011
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 20-24, Positive 2018 142
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 25-49, Negative 2018 6,877
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 25-49, Positive 2018 162
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 50+, Negative 2018 1,144
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 50+, Positive 2018 13
HTC_TST_DSD Service Delivery Point (Facility)Other PITC: <1, Negative 2018 306
HTC_TST_DSD Sum of Test Result disaggregates 2018 17,039
HTC_TST_TA By Test Result: Positive 2018 6,625
HTC_TST_TA Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 88,090
HTC_TST_TA Service Delivery Point (Facility) ANC: 15-19, Negative 2018 6,883
HTC_TST_TA Service Delivery Point (Facility) ANC: 15-19, Positive 2018 243
HTC_TST_TA Service Delivery Point (Facility) ANC: 20-24, Negative 2018 8,027
HTC_TST_TA Service Delivery Point (Facility) ANC: 20-24, Positive 2018 272
HTC_TST_TA Service Delivery Point (Facility) ANC: 25-49, Negative 2018 6,883
HTC_TST_TA Service Delivery Point (Facility) ANC: 25-49, Positive 2018 243
HTC_TST_TA Service Delivery Point (Facility) ANC: 50+, Negative 2018 1,149
HTC_TST_TA Service Delivery Point (Facility) ANC: 50+, Positive 2018 39
HTC_TST_TA Service Delivery Point (Facility) Index: 1-9, Negative 2018 73
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 54
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 32
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 10
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 4
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 234
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 132
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 71
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 39
HTC_TST_TA Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 1,636
HTC_TST_TA Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 921
HTC_TST_TA Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 2,239
HTC_TST_TA Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 1,260
HTC_TST_TA Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 153
HTC_TST_TA Service Delivery Point (Facility) Index: 50+, Female, Positive 2018 86
HTC_TST_TA Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 276
HTC_TST_TA Service Delivery Point (Facility) Index: 50+, Male, Positive 2018 156
HTC_TST_TA Service Delivery Point (Facility) Index: <1, Negative 2018 73
HTC_TST_TA Service Delivery Point (Facility) Index: <1, Positive 2018 2
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative 2018 147
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive 2018 1
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 328
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2018 17
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 42
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2018 2
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 1,356
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 62
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 347
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2018 16
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 7,486
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 410
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 8,217
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 492
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2018 768
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2018 42
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2018 1,063
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2018 63
HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Negative 2018 89
HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Positive 2018 2
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 171
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 1
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 1
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 3
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 416
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 24
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 35
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 2
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 1,818
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 107
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 395
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 26
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 10,158
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 711
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 11,002
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 859
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 1,010
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 63
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 1,359
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 103
HTC_TST_TA Service Delivery Point (Facility) Other PITC: <1, Negative 2018 103
HTC_TST_TA Service Delivery Point (Facility) Other PITC: <1, Positive 2018 2
HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Negative 2018 176
HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Positive 2018 2
HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 6
HTC_TST_TA Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 84
HTC_TST_TA Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 39
HTC_TST_TA Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 90
HTC_TST_TA Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 34
HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 1
HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 8
HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive 2018 1
HTC_TST_TA Service Delivery Point (Facility) VMMC: 15-19, Negative 2018 2,110
HTC_TST_TA Service Delivery Point (Facility) VMMC: 15-19, Positive 2018 15
HTC_TST_TA Service Delivery Point (Facility) VMMC: 20-24, Negative 2018 2,452
HTC_TST_TA Service Delivery Point (Facility) VMMC: 20-24, Positive 2018 50
HTC_TST_TA Service Delivery Point (Facility) VMMC: 25-49, Negative 2018 2,110
HTC_TST_TA Service Delivery Point (Facility) VMMC: 25-49, Positive 2018 48
HTC_TST_TA Service Delivery Point (Facility) VMMC: 50+, Negative 2018 353
HTC_TST_TA Service Delivery Point (Facility) VMMC: 50+, Positive 2018 2
HTC_TST_TA Sum of Test Result disaggregates 2018 6,625
KP_PREV_DSD By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 11,659
KP_PREV_DSD By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 8,096
KP_PREV_DSD Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 19,755
OVC_SERV_DSD Age/Sex: 1-9 2018 7,133
OVC_SERV_DSD Age/Sex: 10-14 Female 2018 2,820
OVC_SERV_DSD Age/Sex: 10-14 Male 2018 1,940
OVC_SERV_DSD Age/Sex: 15-17 Female 2018 1,500
OVC_SERV_DSD Age/Sex: 15-17 Male 2018 1,841
OVC_SERV_DSD Age/Sex: <1 2018 850
OVC_SERV_DSD By: Age/sex: 18-24 Female 2018 2,276
OVC_SERV_DSD By: Age/sex: 25+ Female 2018 641
OVC_SERV_DSD By: Age/sex: Male 18-24 2018 1,955
OVC_SERV_DSD By: Age/sex: Male 25+ 2018 453
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2018 21,409
OVC_SERV_DSD Program Completion: Active 2018 16,163
OVC_SERV_DSD Program Completion: Exited without graduation 2018 1,065
OVC_SERV_DSD Program Completion: Graduation 2018 3,103
OVC_SERV_DSD Program Completion: Transferred 2018 1,078
OVC_SERV_DSD Sum of Age/Sex disaggregates 2018 8,101
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2018 1,623
PMTCT_ART_DSD New on ART 2018 1,345
PMTCT_ART_DSD Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 2,968
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 47,209
PMTCT_ART_TA Already on ART at beginning of current pregnancy 2018 951
PMTCT_ART_TA New on ART 2018 795
PMTCT_ART_TA Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 1,746
PMTCT_ART_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 27,295
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 2,399
PMTCT_EID_DSD Number of infants with a negative virological test result between 2 and 12 months of birth 2018 712
PMTCT_EID_DSD Number of infants with a negative virological test result within 2 months of birth 2018 1,586
PMTCT_EID_DSD Number of infants with a positive virological test result between 2 and 12 months of birth 2018 31
PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth 2018 70
PMTCT_EID_TA Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 1,411
PMTCT_EID_TA Number of infants with a negative virological test result between 2 and 12 months of birth 2018 418
PMTCT_EID_TA Number of infants with a negative virological test result within 2 months of birth 2018 935
PMTCT_EID_TA Number of infants with a positive virological test result between 2 and 12 months of birth 2018 15
PMTCT_EID_TA Number of infants with a positive virological test result within 2 months of birth 2018 43
PMTCT_STAT_DSD By Age (Denominator): 10-14 2018 474
PMTCT_STAT_DSD By Age (Denominator): 20-24 2018 8,972
PMTCT_STAT_DSD By Age (Denominator): 25-49 2018 28,791
PMTCT_STAT_DSD By Age (Denominator): <15-19 2018 8,972
PMTCT_STAT_DSD By Age (Numerator): 10-14 2018 474
PMTCT_STAT_DSD By Age (Numerator): 15-19 2018 8,972
PMTCT_STAT_DSD By Age (Numerator): 20-24 2018 8,972
PMTCT_STAT_DSD By Age (Numerator): 25-49 2018 28,791
PMTCT_STAT_DSD By Number of known positives: 10-14 2018 14
PMTCT_STAT_DSD By Number of known positives: 15-19 2018 301
PMTCT_STAT_DSD By Number of known positives: 20-24 2018 538
PMTCT_STAT_DSD By Number of known positives: 25-49 2018 734
PMTCT_STAT_DSD By Number of new negative: 10-14 2018 447
PMTCT_STAT_DSD By Number of new negative: 15-19 2018 8,378
PMTCT_STAT_DSD By Number of new negative: 20-24 2018 7,912
PMTCT_STAT_DSD By Number of new negative: 25-49 2018 27,348
PMTCT_STAT_DSD By Number of new positives: 10-14 2018 13
PMTCT_STAT_DSD By Number of new positives: 15-19 2018 293
PMTCT_STAT_DSD By Number of new positives: 20-24 2018 522
PMTCT_STAT_DSD By Number of new positives: 25-49 2018 709
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 47,209
PMTCT_STAT_TA By Age (Denominator): 10-14 2018 273
PMTCT_STAT_TA By Age (Denominator): 15-19 2018 5,186
PMTCT_STAT_TA By Age (Denominator): 20-24 2018 5,186
PMTCT_STAT_TA By Age (Denominator): 25-49 2018 16,650
PMTCT_STAT_TA By Age (Numerator): 10-14 2018 273
PMTCT_STAT_TA By Age (Numerator): 20-24 2018 5,186
PMTCT_STAT_TA By Age (Numerator): 25-49 2018 16,650
PMTCT_STAT_TA By Age (Numerator): : 15-19 2018 5,186
PMTCT_STAT_TA By known positives: 10-14 2018 2
PMTCT_STAT_TA By known positives: 15-19 2018 184
PMTCT_STAT_TA By known positives: 20-24 2018 326
PMTCT_STAT_TA By known positives: 25-49 2018 451
PMTCT_STAT_TA By new negatives: 10-14 2018 269
PMTCT_STAT_TA By new negatives: 15-19 2018 4,835
PMTCT_STAT_TA By new negatives: 20-24 2018 4,565
PMTCT_STAT_TA By new negatives: 25-49 2018 15,789
PMTCT_STAT_TA By new positives: 10-14 2018 2
PMTCT_STAT_TA By new positives: 15-19 2018 167
PMTCT_STAT_TA By new positives: 20-24 2018 295
PMTCT_STAT_TA By new positives: 25-49 2018 410
PMTCT_STAT_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 27,295
PP_PREV_DSD Age/sex: 10-14 Female 2018 3,899
PP_PREV_DSD Age/sex: 10-14 Male 2018 3,222
PP_PREV_DSD Age/sex: 15-19 Female 2018 3,555
PP_PREV_DSD Age/sex: 15-19 Male 2018 6,272
PP_PREV_DSD Age/sex: 20-24 Female 2018 3,684
PP_PREV_DSD Age/sex: 20-24 Male 2018 10,730
PP_PREV_DSD Age/sex: 25-49 Female 2018 4,628
PP_PREV_DSD Age/sex: 25-49 Male 2018 22,219
PP_PREV_DSD Age/sex: 50+ Female 2018 385
PP_PREV_DSD Age/sex: 50+ Male 2018 476
PP_PREV_DSD Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 59,070
PP_PREV_DSD Sum of Age/Sex disaggregates 2018 59,070
PrEP_NEW_DSD Female 15-19 2018 176
PrEP_NEW_DSD Female 20-24 2018 176
PrEP_NEW_DSD Female 25-49 2018 176
PrEP_NEW_DSD Female 50+ 2018 168
PrEP_NEW_DSD FSW 2018 126
PrEP_NEW_DSD Male 15-19 2018 176
PrEP_NEW_DSD Male 20-24 2018 176
PrEP_NEW_DSD Male 25-49 2018 176
PrEP_NEW_DSD Male 50+ 2018 176
PrEP_NEW_DSD MSM 2018 5
PrEP_NEW_DSD Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2018 1,400
PrEP_NEW_DSD TG 2018 1
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 186
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 173
TB_ART_DSD Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 14
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 13
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 338
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 325
TB_ART_DSD Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 21
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 19
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 559
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 530
TB_ART_TA Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 42
TB_ART_TA Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 42
TB_ART_TA Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1
TB_ART_TA Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1
TB_ART_TA Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 89
TB_ART_TA Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 84
TB_ART_TA Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 3
TB_ART_TA Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 3
TB_ART_TA The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 135
TB_ART_TA The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 130
TB_PREV_DSD By Age/Sex (Denominator): 15+, Female 2018 7,121
TB_PREV_DSD By Age/Sex (Denominator): 15+, Male 2018 9,025
TB_PREV_DSD By Age/Sex (Denominator): <15, Female 2018 88
TB_PREV_DSD By Age/Sex (Denominator): <15, Male 2018 69
TB_PREV_DSD By Age/Sex (Numerator): 15+, Female 2018 3,563
TB_PREV_DSD By Age/Sex (Numerator): 15+, Male 2018 4,523
TB_PREV_DSD By Age/Sex (Numerator): <15, Female 2018 35
TB_PREV_DSD By Age/Sex (Numerator): <15, Male 2018 31
TB_PREV_DSD By Therapy type (Denominator): 6-12 Month IPT 2018 16,303
TB_PREV_DSD By Therapy type (Numerator): 6-12 Month IPT 2018 8,152
TB_PREV_DSD The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 8,152
TB_PREV_DSD The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 16,303
TB_PREV_TA By Age/Sex (Denominator): 15+, Female 2018 1,546
TB_PREV_TA By Age/Sex (Denominator): 15+, Male 2018 2,055
TB_PREV_TA By Age/Sex (Denominator): <15, Female 2018 23
TB_PREV_TA By Age/Sex (Denominator): <15, Male 2018 7
TB_PREV_TA By Age/Sex (Numerator): 15+, Female 2018 776
TB_PREV_TA By Age/Sex (Numerator): 15+, Male 2018 1,039
TB_PREV_TA By Age/Sex (Numerator): <15, Female 2018 1
TB_PREV_TA By Age/Sex (Numerator): <15, Male 2018 1
TB_PREV_TA By Therapy type (Denominator): 6-12 Month IPT 2018 3,631
TB_PREV_TA By Therapy type (Numerator): 6-12 Month IPT 2018 1,817
TB_PREV_TA The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 1,817
TB_PREV_TA The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 3,631
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 391
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 391
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 36
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 36
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 702
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 702
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 45
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 45
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 1,174
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2018 1,174
TB_STAT_TA Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 96
TB_STAT_TA Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 96
TB_STAT_TA Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 7
TB_STAT_TA Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 7
TB_STAT_TA Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 181
TB_STAT_TA Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 181
TB_STAT_TA Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 10
TB_STAT_TA Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 10
TB_STAT_TA Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 294
TB_STAT_TA Total number of registered new and relapsed TB cases, during the reporting period 2018 294
TX_CURR_DSD Age/Sex: 10-14 Female 2018 418
TX_CURR_DSD Age/Sex: 10-14 Male 2018 289
TX_CURR_DSD Age/Sex: 15-19 Female 2018 1,268
TX_CURR_DSD Age/Sex: 15-19 Male 2018 310
TX_CURR_DSD Age/Sex: 20-24 Female 2018 4,018
TX_CURR_DSD Age/Sex: 20-24 Male 2018 1,320
TX_CURR_DSD Age/Sex: 25-49 Female 2018 21,019
TX_CURR_DSD Age/Sex: 25-49 Male 2018 14,677
TX_CURR_DSD Age/Sex: 50+ Female 2018 2,079
TX_CURR_DSD Age/Sex: 50+ Male 2018 1,812
TX_CURR_DSD Age/Sex: <1 2018 85
TX_CURR_DSD Age/Sex: <1-9 2018 1,296
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2018 48,591
TX_CURR_DSD Sum of age/sex disaggregates 2018 1,578
TX_CURR_TA Age/Sex: 1-9 2018 288
TX_CURR_TA Age/Sex: 10-14 Female 2018 91
TX_CURR_TA Age/Sex: 10-14 Male 2018 69
TX_CURR_TA Age/Sex: 15-19 Female 2018 240
TX_CURR_TA Age/Sex: 15-19 Male 2018 54
TX_CURR_TA Age/Sex: 20-24 Female 2018 761
TX_CURR_TA Age/Sex: 20-24 Male 2018 238
TX_CURR_TA Age/Sex: 25-49 Female 2018 4,605
TX_CURR_TA Age/Sex: 25-49 Male 2018 3,265
TX_CURR_TA Age/Sex: 50+ Female 2018 456
TX_CURR_TA Age/Sex: 50+ Male 2018 403
TX_CURR_TA Age/Sex: <1 2018 17
TX_CURR_TA Number of adults and children receiving antiretroviral therapy (ART) 2018 10,487
TX_CURR_TA Sum of Age/Sex disaggregations 2018 294
TX_NEW_DSD Breastfeeding status 2018 55
TX_NEW_DSD By Age/Sex: 1-9 2018 27
TX_NEW_DSD By Age/Sex: 10-14 Female 2018 4
TX_NEW_DSD By Age/Sex: 10-14 Male 2018 7
TX_NEW_DSD By Age/Sex: 15-19 Female 2018 258
TX_NEW_DSD By Age/Sex: 15-19 Male 2018 60
TX_NEW_DSD By Age/Sex: 20-24 Female 2018 832
TX_NEW_DSD By Age/Sex: 20-24 Male 2018 265
TX_NEW_DSD By Age/Sex: 25-49 Female 2018 6,203
TX_NEW_DSD By Age/Sex: 25-49 Male 2018 8,639
TX_NEW_DSD By Age/Sex: 50+ Female 2018 616
TX_NEW_DSD By Age/Sex: 50+ Male 2018 1,068
TX_NEW_DSD By Age/Sex: <1 2018 132
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 18,111
TX_NEW_DSD Pregnancy status 2018 4,533
TX_NEW_DSD Sum of Age/Sex disaggregates 2018 17,952
TX_NEW_TA Breastfeeding status 2018 8
TX_NEW_TA By Age/Sex: 1-9 2018 2
TX_NEW_TA By Age/Sex: 15-19 Female 2018 51
TX_NEW_TA By Age/Sex: 15-19 Male 2018 10
TX_NEW_TA By Age/Sex: 20-24 Female 2018 188
TX_NEW_TA By Age/Sex: 20-24 Male 2018 63
TX_NEW_TA By Age/Sex: 25-49 Female 2018 1,349
TX_NEW_TA By Age/Sex: 25-49 Male 2018 1,969
TX_NEW_TA By Age/Sex: 50+ Female 2018 132
TX_NEW_TA By Age/Sex: 50+ Male 2018 243
TX_NEW_TA By Age/Sex: <1 2018 27
TX_NEW_TA Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 4,034
TX_NEW_TA Pregnancy status 2018 1,012
TX_NEW_TA Sum of Age/Sex disaggregates 2018 4,005
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 25,538
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 16,313
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 1,041
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 843
TX_PVLS_DSD Denominator: Indication: Routine 2018 43,735
TX_PVLS_DSD Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 221
TX_PVLS_DSD Denominator: Preg/BF by Indication: Pregnant Routine 2018 4,376
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 43,735
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 39,362
TX_PVLS_DSD Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 22,996
TX_PVLS_DSD Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 14,677
TX_PVLS_DSD Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 932
TX_PVLS_DSD Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 757
TX_PVLS_DSD Numerator: Indication: Routine 2018 39,362
TX_PVLS_DSD Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 202
TX_PVLS_DSD Numerator: Preg/BF by Indication: Pregnant Routine 2018 3,941
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 5,460
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,560
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 232
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 190
TX_PVLS_TA Denominator: Indication: Routine 2018 9,442
TX_PVLS_TA Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 46
TX_PVLS_TA Denominator: Preg/BF by Indication: Pregnant Routine 2018 942
TX_PVLS_TA Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 9,442
TX_PVLS_TA Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 8,494
TX_PVLS_TA Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 4,919
TX_PVLS_TA Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,203
TX_PVLS_TA Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 203
TX_PVLS_TA Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 169
TX_PVLS_TA Numerator: Indication: Routine 2018 8,494
TX_PVLS_TA Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 46
TX_PVLS_TA Numerator: Preg/BF by Indication: Pregnant Routine 2018 852
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3,529
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 3,176
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 2,091
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,877
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 204
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 203
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 179
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 178
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 5,434
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 6,003
TX_RET_TA Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,483
TX_RET_TA Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,333
TX_RET_TA Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 881
TX_RET_TA Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 786
TX_RET_TA Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 87
TX_RET_TA Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 87
TX_RET_TA Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 75
TX_RET_TA Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 75
TX_RET_TA Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 2,281
TX_RET_TA Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 2,526
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Female 2018 1,152
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Male 2018 936
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Female 2018 28,377
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Male 2018 18,126
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 2,724
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 388
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 778
TX_TB_DSD Denominator: By Screen Result: Negative 2018 44,701
TX_TB_DSD Denominator: By Screen Result: Positive 2018 3,890
TX_TB_DSD Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 3,890
TX_TB_DSD Number of ART patients who were screened for TB at least once during the reporting period 2018 48,591
TX_TB_DSD Number of ART patients who were started on TB treatment during the reporting period 2018 970
TX_TB_DSD Numerator: By Aggregated Age/Sex: 15+, Female 2018 570
TX_TB_DSD Numerator: By Aggregated Age/Sex: 15+, Male 2018 363
TX_TB_DSD Numerator: By Aggregated Age/Sex: <15, Female 2018 20
TX_TB_DSD Numerator: By Aggregated Age/Sex: <15, Male 2018 17
TX_TB_TA Denominator: By Aggregated Age/Sex: 15+, Female 2018 6,069
TX_TB_TA Denominator: By Aggregated Age/Sex: 15+, Male 2018 3,953
TX_TB_TA Denominator: By Aggregated Age/Sex: <15, Female 2018 255
TX_TB_TA Denominator: By Aggregated Age/Sex: <15, Male 2018 210
TX_TB_TA Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 583
TX_TB_TA Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 86
TX_TB_TA Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 169
TX_TB_TA Denominator: By Screen Result: Negative 2018 9,649
TX_TB_TA Denominator: By Screen Result: Positive 2018 838
TX_TB_TA Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 838
TX_TB_TA Number of ART patients who were screened for TB at least once during the reporting period 2018 10,487
TX_TB_TA Number of ART patients who were started on TB treatment during the reporting period 2018 210
TX_TB_TA Numerator: By Aggregated Age/Sex: 15+, Female 2018 122
TX_TB_TA Numerator: By Aggregated Age/Sex: 15+, Male 2018 87
TX_TB_TA Numerator: By Aggregated Age/Sex: <15, Female 2018 1
VMMC_CIRC_DSD By Age: 10-14 2018 3,382
VMMC_CIRC_DSD By Age: 15-19 2018 6,083
VMMC_CIRC_DSD By Age: 20-24 2018 8,113
VMMC_CIRC_DSD By Age: 25-29 2018 12,846
VMMC_CIRC_DSD By Age: 30-49 2018 2,027
VMMC_CIRC_DSD By Age: 50+ 2018 1,350
VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 2018 319
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2018 2,863
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 33,801
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2018 33,801
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2018 18,928
Cross Cutting Budget Categories and Known Amounts Total: $1,874,000
Key Populations: MSM and TG $10,000
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Training of health workers and community outreach workers
Key Populations: FSW $40,000
Monitoring and evaluation of SW programs
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Collection and use of strategic information on SWs and clients
Training of health workers and community outreach workers
Gender: Gender Based Violence (GBV) $130,000
GBV Prevention
Implementation
Capacity building
Monitoring and Evaluation
Collection and Use of Gender-related Strategic Information
Food and Nutrition: Commodities $10,000
Condoms: Policy, Tools, and Services $12,000
Motor Vehicles: Purchased $150,000
Human Resources for Health $110,000
Economic Strengthening $10,000
Construction $1,400,000
Food and Nutrition: Policy, Tools, and Service Delivery $2,000